Lilly drug slows Alzheimer’s progression by 35% in trial.
In a promising development for Alzheimer's disease treatment, Lilly drug from Eli Lilly and Company has been found to slow Alzheimer's progression of the disease by 35% in a clinical trial. The drug, called donanemab, works by targeting a protein called amyloid beta, which is believed to play a...
Read more